Ignite Creation Date:
2024-05-06 @ 6:07 PM
Last Modification Date:
2024-10-26 @ 2:42 PM
Study NCT ID:
NCT05553314
Status:
RECRUITING
Last Update Posted:
2023-11-08
First Post:
2022-09-20
Brief Title:
Carvedilol in HF With Preserved EF
Sponsor:
Seoul National University Bundang Hospital
Organization:
Seoul National University Bundang Hospital
Study Overview
Official Title:
Slow-release CArvedilol in Patients With REduced Strain and Preserved Ejection Fraction Heart Failure CARE-preserved HF A Prospective Randomized Double-Blinded Multicenter Study
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction HFrEF but not in those with preserved EF Global longitudinal strain GLS is a prognostic factor independent of left ventricular ejection fraction LVEF In a retrospective with 1969 patients with HF and LVEF of 40 beta-blocker was associated with improved survival in those with low GLS GLS 14 but not in those with GLS 14 In this prospective randomized clinical study the investigators will assess the effect of slow-release carvedilol in patients with HFpEF and hypertension The primary endpoint is the time-averaged proportional changes in NT-proBNP level and GLS change from baseline to month 6
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None